KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Non-Current Liabilities: 2010-2024

Historic Total Non-Current Liabilities for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $235.9 million.

  • Nektar Therapeutics' Total Non-Current Liabilities fell 16.23% to $211.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $211.2 million, marking a year-over-year decrease of 16.23%. This contributed to the annual value of $235.9 million for FY2024, which is 10.11% down from last year.
  • Per Nektar Therapeutics' latest filing, its Total Non-Current Liabilities stood at $235.9 million for FY2024, which was down 10.11% from $262.4 million recorded in FY2023.
  • Nektar Therapeutics' Total Non-Current Liabilities' 5-year high stood at $452.5 million during FY2020, with a 5-year trough of $235.9 million in FY2024.
  • In the last 3 years, Nektar Therapeutics' Total Non-Current Liabilities had a median value of $262.4 million in 2023 and averaged $278.2 million.
  • Data for Nektar Therapeutics' Total Non-Current Liabilities shows a maximum YoY declined of 22.00% (in 2023) over the last 5 years.
  • Over the past 5 years, Nektar Therapeutics' Total Non-Current Liabilities (Yearly) stood at $452.5 million in 2020, then decreased by 9.40% to $410.0 million in 2021, then decreased by 17.94% to $336.4 million in 2022, then declined by 22.00% to $262.4 million in 2023, then dropped by 10.11% to $235.9 million in 2024.